Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INSPIRE MEDICAL SYSTEMS, INC.

(INSP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inspire Medical : Company Presentation August 2021

08/03/2021 | 07:56pm EDT

Inspire Medical Systems, Inc.

August 2021

NYSE: INSP

Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward- looking statements. In some cases, you can identify forward-looking statements by terms such as ''may,'' ''will,'' ''should,'' ''expect,'' ''plan,'' ''anticipate,'' ''could,'' "future," "outlook," ''intend,'' ''target,'' ''project,'' ''contemplate,'' ''believe,'' ''estimate,'' ''predict,'' ''potential,'' ''continue,'' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this presentation relate to, among other things, statements regarding the impact of the COVID-19 pandemic on our business operations, financial results and financial condition, investments in our business, our growth strategies, our expectation that a substantial portion of postponed Inspire therapy procedures will be rescheduled, our expectations regarding the final reimbursement levels for Inspire therapy procedures, the activity of our commercial team once circumstances allow, full year 2021 financial and operational outlook, and positive insurance coverage of Inspire therapy and improvements in market access, clinical data growth, product development, indication expansion, market development, and prior authorization approvals.

These forward-looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Inspire therapy; the impact of the ongoing and global COVID- 19 pandemic; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; the timing or likelihood of regulatory filings and approvals; risks related to our debt and capital structure; our ability to establish and maintain intellectual property protection for our Inspire therapy and system or avoid claims of infringement; tax risks; risks that we may be deemed an investment company under the Investment Company Act of 1940; regulatory risks; the volatility of the trading price of our common stock; and our expectations about market trends. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this presentation can be found under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2020, as updated in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

© Inspire Medical Systems, Inc.

2All Rights Reserved

INSPIRE CONFIDENTIAL

© Inspire Medical Systems, Inc.

3All Rights Reserved

INSPIRE CONFIDENTIAL

Strong Momentum in Therapy Adoption in 2021!!!

  • FY 2021 Guidance revised post-Q2:
    • Revenue: $210M - $213M, representing 82% - 85% growth from FY 2020 revenue of $115.4M
      • Prior guidance of $192M - $196M post-Q1 financials
    • Gross margin: 85% - 86%
    • Territories: 10 to 11 new territories per quarter
    • U.S. centers: 48 to 52 new centers per quarter
  • In 2021, focus is on continuing expansion by improving capacityand conversion:
    • Increasing capacity by adding territories and centers (hospitals and ASC networks)
      • Entered into a network agreement with CHS, a publicly held hospital system with 84 hospitals and approximately 30 Ambulatory Surgical Centers across 16 states
      • USPI recently entered a joint venture which increased the number of USPI locations from over 300 to over 500 potentials locations. Inspire has opened approximately 20 USPI centers to-date.
    • New direct-to-consumer TV campaigns are driving more website visitors
    • Increasing and improving connections with potential patients with continued expansion of the Advisor Care Program (call center) to new and existing centers to capture most in-bound phone calls

© Inspire Medical Systems, Inc.

4All Rights Reserved

INSPIRE CONFIDENTIAL

Strong Momentum in Therapy Adoption in 2021!!!

  • Strong enthusiasm and acceptance of the FDA-approvedtwo-incision implanting approach
    • 99% of Inspire procedures now utilize this technique which significantly reduces surgical time
  • Recent Anthem coverage policy -- approvals now occurring in just days for new Anthem patients and efficient approval of previous denials
  • Approximately 50 new ENT surgeons recently completed the inaugural Inspire Fellows Program and are joining new and existing centers
  • Resuming and increasing the number of Sleep Innovation Center events at headquarters which educates and strengthens relationships with sleep docs
  • Planning and training has begun with Japan LifeLine Co., with first implants anticipated later in 2021
  • Positive news regarding proposed payment for new dedicated CPT code for Inspire procedure
    • Physician payment of $870 representing a range of $8.50-$10.00 per minute of procedure time
    • Hospital payment continues to map to Level V Neuro Ambulatory Procedure Code (APC) and proposed by CMS for a 3% increase in 2022
    • Ambulatory Surgical Center (ASC) calculation missing history of Inspire implants that will be presented to CMS at the August panel date around Inspire procedures to retain current ASC payment level

© Inspire Medical Systems, Inc.

5All Rights Reserved

INSPIRE CONFIDENTIAL

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Inspire Medical Systems Inc. published this content on 03 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2021 23:55:03 UTC.


© Publicnow 2021
All news about INSPIRE MEDICAL SYSTEMS, INC.
09/15INSPIRE MEDICAL : Announces Quality Week and Launch of the Patient Experience Re..
AQ
08/30Inspire Medical Systems, Inc. Announces Recommendation by Medicare Panel to I..
GL
08/26Inspire Medical Systems, Inc. to Present at the Wells Fargo 2021 Virtual Heal..
GL
08/04INSPIRE MEDICAL : SVB Leerink Adjusts Inspire Medical Systems' Price Target to $..
MT
08/04INSPIRE MEDICAL : Posts Narrower Q2 Loss as Revenue Surges
MT
08/04INSPIRE MEDICAL : Piper Sandler Adjusts Price Target on Inspire Medical Systems ..
MT
08/04INSPIRE MEDICAL SYSTEMS, INC. : Regulation FD Disclosure (form 8-K)
AQ
08/03INSPIRE MEDICAL : Company Presentation August 2021
PU
08/03INSPIRE : Q2 Earnings Snapshot
AQ
08/03INSPIRE MEDICAL : Announces Second Quarter 2021 Financial Results and Updates 20..
PU
More news
Analyst Recommendations on INSPIRE MEDICAL SYSTEMS, INC.
More recommendations
Financials (USD)
Sales 2021 213 M - -
Net income 2021 -59,7 M - -
Net cash 2021 130 M - -
P/E ratio 2021 -114x
Yield 2021 -
Capitalization 6 798 M 6 798 M -
EV / Sales 2021 31,3x
EV / Sales 2022 23,1x
Nbr of Employees 341
Free-Float 97,2%
Chart INSPIRE MEDICAL SYSTEMS, INC.
Duration : Period :
Inspire Medical Systems, Inc. Technical Analysis Chart | INSP | US4577301090 | MarketScreener
Technical analysis trends INSPIRE MEDICAL SYSTEMS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 249,26 $
Average target price 254,00 $
Spread / Average Target 1,90%
EPS Revisions
Managers and Directors
Timothy P. Herbert President, Chief Executive Officer & Director
Richard John Buchholz Chief Financial Officer
Marilyn Carlson Nelson Chairman
Quan Ni Vice President-Research & Clinical Affairs
Philip J. Ebeling Chief Operating Officer
Sector and Competitors